Company intelligence / Profile preview

Nanjing Shenzhou Jiamei Pharmaceutical

Nanjing, Jiangsu, Chinafr.acrobiosystems.com ↗

Ownership: Private
Development stage: Other

Overview

Nanjing Shenzhou Jiamei Pharmaceutical is a private Chinese pharmaceutical company focused on the research and development of small molecule drugs targeting various disease areas including infectious, immune, nervous system, digestive, and congenital disorders. The company has at least four small molecule programs in its pipeline with targets such as JAK1 and proton pumps. One notable product is Keverprazan hydrochloride ("Keprasen hydrochloride"), which has been evaluated in clinical trials for pharmacokinetics and safety in patients with hepatic insufficiency as recently as November 2024.

Therapeutic areas: Rare DiseasesNeurologyInfectious DiseasesGastroenterologyImmunology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Nanjing Shenzhou Jiamei Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanjing Shenzhou Jiamei Pharmaceutical.

Explore the full profile